Business Context and Reporting Period
Important issuer discrepancy: Although the request identifies Scilex Holding Co., the supplied Form 10-Q is for Vickers Vantage Corp. I, a Cayman Islands blank-check company. This summary reflects the filing provided, not a Scilex filing.
The filing covers the quarter ended September 30, 2021. Vickers had not commenced operations and was seeking a business combination; it reported no operating revenue. Its IPO closed January 11, 2021, and it placed $139.38 million in a trust account for a future combination or shareholder redemptions.
Financial Results and Position
| Metric | Three months ended September 30, 2021 | Nine months ended September 30, 2021 |
|---|---|---|
| Revenue | None | None |
| Operating and formation costs | $283,346 | $620,642 |
| Net loss | $1,444,352 | $349,248 |
| Basic and diluted loss per share | $0.08 | $0.02 |
| Net cash used in operating activities | $693,609 for the nine months |
Q3 net loss included a $1.163 million loss from the change in fair value of private warrants, partly offset by $1,794 of trust-account interest. The nine-month result included a $2.873 million warrant fair-value gain, a $2.599 million loss on initial issuance of private warrants, and $28,006 of trust interest.
At September 30, 2021, cash outside the trust was $115,642; trust-account investments were $139.408 million; current assets were $232,178; and working capital was $188,609. Total liabilities were $10.090 million, including a $4.856 million private-warrant liability and $5.190 million deferred underwriting fee payable. The company reported no long-term debt or lease obligations. The deferred fee is payable from trust funds upon completion of a business combination.
Cash from financing activities was $140.159 million for the nine months, principally from the IPO and private-warrant sale; investing cash outflow of $139.380 million reflects the trust deposit. No operating cash flow or profit margin is meaningful because the company had no operations or revenue.
Changes Versus Prior Comparable Period
For Q3 2020, the company reported an $856 net loss; for the period from inception through September 30, 2020, the net loss was $5,856. The substantially higher 2021 expenses and losses reflect the IPO, public-company and transaction-related activity, and warrant accounting. The 2020 periods were before the January 2021 IPO, so they are not directly comparable in scale.
The company revised its presentation to classify all redeemable public shares as temporary equity and to recognize accretion to redemption value. It stated that the revision did not change total assets, liabilities, or operating results; it did materially change the presentation of equity and accumulated deficit.
Outlook, Risks, and Unusual Items
- The company had until January 11, 2022 to complete a business combination, with up to two three-month extensions through July 11, 2022. Each extension required a $1.035 million sponsor or affiliate deposit into trust; the sponsors intended, but were not obligated, to fund extensions.
- Management disclosed substantial doubt about the company’s ability to continue as a going concern through July 11, 2022 if it failed to complete a business combination. The filing says additional financing might be unavailable and that liquidity constraints could require conserving cash or suspending the search.
- If no combination is completed within the permitted period, public shares are to be redeemed and warrants may expire worthless. The trust is generally reserved for a combination or redemptions, not ordinary operating expenses.
- COVID-19 could adversely affect the company’s financial position or target search, but the specific impact was not determinable. Management also noted uncertainty in the fair-value estimates for private warrants.
- Management reported disclosure controls were effective and stated that a previously identified material weakness in internal control had been remediated by June 30, 2021.
Key Facts Investors Should Verify
- Confirm the issuer: the supplied filing is Vickers Vantage Corp. I, not Scilex Holding Co.
- Review the revised temporary-equity presentation and its effect on reported shareholders’ deficit; distinguish this accounting revision from changes in operating results.
- Verify business-combination progress, any extension funding, redemption levels, and remaining deadline against subsequent filings.
- Assess available operating cash separately from the $139.4 million trust balance, and review the going-concern warning and deferred underwriting fee.
- Review the valuation assumptions and potential earnings volatility associated with the private-warrant liability.